Morepen Laboratories

Solan, India Founded: 1984 • Age: 42 yrs Listed
API, formulations, diagnostics, and FMHG products are manufactured and marketed.
Request Access
Report Incorrect Data
Page last updated

About Morepen Laboratories

Morepen Laboratories is a publicly listed company based in Solan (India) founded in 1984. API, formulations, diagnostics, and FMHG products are manufactured and marketed. The company has 1,104 employees. Its chief executive, as recorded, is Sanjay Suri. Its website morepen.com draws about 20 thousand monthly visits. Its Indian entity Morepen Laboratories Limited reported revenue of ₹1,853 Cr. Morepen Laboratories offers products and services including Active Pharmaceutical Ingredients and Home Diagnostics. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.

Company details

Morepen Laboratories was established in 1984 in Solan, India, within the pharmaceuticals sector. Active pharmaceutical ingredients, formulations, diagnostic tools, and fast-moving health goods are produced and distributed. Over-the-counter healthcare items, nutraceuticals, wellness solutions, and healthy cures form part of the portfolio. Self-care devices, including blood pressure and glucose monitors, are also supplied to support consumer health needs.

  • Headquarters Solan, India
  • Employees 1,104
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website morepen.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Morepen Laboratories Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹5,433 Cr

    MOREPENLAB · NSE

  • Share Price
    ₹99.50

    +0.35% today

  • Revenue
    ₹1,806 Cr

    FY 2025-26 · -0.3% YoY

  • EBITDA
    ₹126 Cr

    Margin 7.0%

  • Net Profit
    ₹63.79 Cr

    FY 2025-26 · -46.0% YoY

  • P/E (TTM)
    27.4x

    P/B 3.8x

  • ROE
    5.4%

    ROCE 7.9%

  • Debt / Equity
    0.13

    Interest cover 18.4x

  • Latest Funding Round
    $59.16M (USD), Post-IPO

    May 2021

  • Investors
    Corinth Group of Switzerland
  • Employee Count
    1,104

Products & Services of Morepen Laboratories

Morepen Laboratories offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and Home Diagnostics.

Active Pharmaceutical Ingredients
Pharmaceuticals

Active pharmaceutical ingredients are produced by Morepen for various therapeutic uses in global markets.

Home Diagnostics
Medical Devices

Home diagnostics products such as blood glucose and blood pressure monitors are manufactured by Morepen for self-care purposes.

Apps and channels of Morepen Laboratories

its YouTube channel Morepen Laboratories Limited India has 162 subscribers.

Morepen Laboratories Limited India
YouTube 162 subscribers Howto & Style
Open channel

Funding Insights of Morepen Laboratories

  • Total Rounds 2
  • Last Round Post-IPO — $59.16M
  • First Round $100M

    (Apr 2021)

  • Investors Count 1

All 2 funding rounds of Morepen Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2021$59.16MPost-IPO––
Corinth Group of Switzerland
Apr 2021$100MPost-IPO––
Corinth Group of Switzerland
Valuation history

1 investors in total: 1 institutional.

Investors in Morepen Laboratories

Morepen Laboratories has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Corinth Group of Switzerland.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Corinth Group of Switzerland
corinthinvest.com
Premium access

Investor details for Morepen Laboratories

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Morepen Laboratories Limited (Morepen Laboratories)

Morepen Laboratories Limited is the primary company behind Morepen Laboratories. The board of Morepen Laboratories Limited currently have 6 directors; the longest-serving is Sushil Suri, appointed in 2015. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sushil Suri
DIN 00012028
Managing Director20 Oct 201511 yrsMorepen Laboratories Limited
Sanjay Suri
DIN 00041590
Whole-time director13 Aug 20197 yrs 2 moMorepen Laboratories Limited
Praveen Kumar Dutt
DIN 06712574
Director13 Aug 20197 yrs 2 moMorepen Laboratories Limited
Savita
DIN 08764773
Director22 Jun 20206 yrs 4 moMorepen Laboratories Limited
Ranjit Khattar
DIN 00726997
Director12 Aug 20242 yrs 2 moMorepen Laboratories Limited
Sharad Jain
DIN 06423452
Director27 Aug 20242 yrs 2 moMorepen Laboratories Limited

People of Morepen Laboratories

41 people are tracked at Morepen Laboratories (16 in leadership, 6 in board & advisors, 19 in team); the tracked headcount is 1,104.

NameRoleGroup
Sanjay Suri
CEOLeadership
Shantanu Tuli
VP, Sales & MarketingLeadership
Ashutosh Sharma
Vice President Sales MarketingLeadership
Naresh Sharma
Vice President OperationsLeadership
Sandeep Garg
Vice President Plant Operations - Medical DevicesLeadership
Jatin Sahni
Vice PresidentLeadership
Samir Sethi
Site Engineering HeadLeadership
R. K. Jain
PresidentLeadership
Madan Pal Tanwar
VP, R&DLeadership
Deepmala Pathak
Assistant General ManagerLeadership
Vivan Prashar
General ManagerLeadership
Priti Mahwar
Chief Marketing OfficerLeadership
Kushal Suri
Director - Sales & Marketing (api’s)Leadership
Muta Srinivas
Head - Business Development (cdmo) API & Finished FormulationsLeadership
Pramod Singh Kaintura
Head Regional Growth - APILeadership
Amita Sharma
VP, Commercial & PPCLeadership
Manoj Joshi
DirectorBoard & advisors
Sukhcharan Singh
DirectorBoard & advisors
Bhupender Raj Wadhwa
DirectorBoard & advisors
Praveen Kumar Dutt
DirectorBoard & advisors

21 more people are available in the full profile.

Premium access

Complete people profiles for Morepen Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Morepen Laboratories

Morepen Laboratories is a publicly listed company on the NSE with ticker symbol MOREPENLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date24 Nov 1999
  • Listed onNSE: MOREPENLAB
  • Listed entityMorepen Laboratories Limited
  • Exchange sectorHealth technology
  • ISININE083A01026
  • Share price₹128.33 (+5% on the day) · 2026-10-14
  • Market capitalisation₹6,674 Cr
  • Price to earnings50.0
  • EPS (diluted, trailing year)₹2.56
  • Dividend yield0.16%
  • Volume (last session)5,785,738

Financials of Morepen Laboratories

Exchange-reported figures of Morepen Laboratories Limited, the listed company behind Morepen Laboratories (NSE: MOREPENLAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,806 Cr
-0.3% YoY
EBITDA
₹126 Cr
-27.8% YoY
Profit After Tax
₹63.79 Cr
-46.0% YoY
Net Worth
₹1,246 Cr
+7.8% YoY
Total Assets
₹1,499 Cr
+12.2% YoY
Total Debt
₹208 Cr
+97.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,8061,8121,6901,4181,5471,188853
Revenue growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
EBITDA12617415979.5313711968.51
EBITDA margin+7.0%+9.6%+9.4%+5.6%+8.8%+10.0%+8.0%
Profit before tax12015513555.7512798.5139.10
Net profit63.7911896.1738.6710297.0933.57
Net profit margin+3.5%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
EPS (₹)1.732.151.880.762.132.160.75
Balance sheet
Total assets1,4991,336915811628471444
Net worth1,2461,156847753579425284
Total debt20810529.0025.1618.5717.05133
Cash & bank68.8349.3652.1256.3145.9767.8938.88
Net working capital720647513459295139153
Cash flow
Cash from operations32.6432.0673.37(91.17)(60.24)50.8311.02
Cash from investing(126)(322)(83.30)(46.51)(31.68)(70.35)(12.46)
Cash from financing97.403005.2014466.3347.275.49
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746570485484412425466453
Revenue growth (YoY)+81.4%+34.1%+4.1%+6.9%-6.0%-6.6%--
Other income8.695.188.463.8130.464.414.615.34
EBITDA12382.5424.4546.3230.7024.1742.2436.14
EBITDA margin+16.5%+14.5%+5.0%+9.6%+7.5%+5.7%+9.1%+8.0%
Depreciation10.078.355.7510.3811.289.0316.474.93
Interest5.194.843.884.324.184.044.671.34
Profit before tax11774.5323.2835.4345.7015.5125.7135.21
Tax27.6518.187.597.934.654.115.418.52
Net profit88.8956.3515.6927.5041.0511.4020.3026.69
EPS (₹)1.621.030.280.500.750.200.350.49
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6811,5551,5381,3391,4491,112792
Revenue growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
EBITDA11215316277.2712911264.47
EBITDA margin+6.7%+9.9%+10.5%+5.8%+8.9%+10.1%+8.1%
Profit before tax89.2613814963.0412694.2437.49
Net profit64.6810211146.2410194.2432.34
Net profit margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
EPS (₹)1.211.852.170.902.122.100.72
Balance sheet
Total assets1,6131,314949836645488474
Net worth1,2431,182889780598445307
Total debt20595.5128.1925.1618.5717.05142
Cash & bank59.4046.3350.4855.9045.5566.9838.03
Net working capital635629515464291133160
Cash flow
Cash from operations20.4729.0877.36(102)(68.87)49.3110.86
Cash from investing(119)(280)(83.60)(36.20)(22.64)(69.09)(12.08)
Cash from financing97.122600.2814466.4147.464.65
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue678541463458370391382403
Revenue growth (YoY)+83.5%+38.3%+21.2%+13.5%-3.7%+1.5%--
Other income8.435.318.823.935.754.093.144.87
Total expenses568461440416342372352372
EBITDA11079.6023.3141.8927.9318.9530.1631.57
EBITDA margin+16.2%+14.7%+5.0%+9.2%+7.6%+4.8%+7.9%+7.8%
Depreciation9.707.980.6310.0910.707.8812.254.81
Interest5.104.783.874.314.113.813.741.27
Profit before tax10472.1527.6331.4218.8711.3517.3130.36
Tax25.7818.157.507.934.493.295.407.69

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746570485484412425466453
Revenue growth (YoY)+81.4%+34.1%+4.1%+6.9%-6.0%-6.6%--
Other income8.695.188.463.8130.464.414.615.34
EBITDA12382.5424.4546.3230.7024.1742.2436.14
EBITDA margin+16.5%+14.5%+5.0%+9.6%+7.5%+5.7%+9.1%+8.0%
Depreciation10.078.355.7510.3811.289.0316.474.93
Interest5.194.843.884.324.184.044.671.34
Profit before tax11774.5323.2835.4345.7015.5125.7135.21
Tax27.6518.187.597.934.654.115.418.52
Net profit88.8956.3515.6927.5041.0511.4020.3026.69
EPS (₹)1.621.030.280.500.750.200.350.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,8061,8121,6901,4181,5471,188853
Revenue growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
Other income47.1418.3613.976.1310.3112.079.48
Total expenses1,6801,6381,5321,3381,4101,070785
Employee cost233209181155164136110
EBITDA12617415979.5313711968.51
EBITDA margin+7.0%+9.6%+9.4%+5.6%+8.8%+10.0%+8.0%
Depreciation36.4328.9833.4727.9327.6430.2836.91
Interest16.418.343.711.98(7.37)1.791.98
Profit before tax12015513555.7512798.5139.10
Tax24.2837.1038.7917.0825.021.425.53
Net profit63.7911896.1738.6710297.0933.57
Net profit margin+3.5%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
EPS (₹)1.732.151.880.762.132.160.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11011010210295.5689.9689.96
Reserves & surplus1,1371,047745651457291194
Shareholders' funds (net worth)1,2461,156847753579425284
Minority interest0.6530.730.00(0.46)(0.46)(0.46)(0.46)
Secured loans44.2453.9629.0025.1618.5717.05133
Unsecured loans16451.140.000.000.000.000.00
Total debt20810529.0025.1618.5717.05133
Total liabilities1,4991,336915811628471444
Assets
Gross block797828621656613628753
Net block513489307267252225216
Capital work in progress21.5528.3424.4517.0114.151.960.00
Investments12484.981.300.000.001.091.09
Inventories272300249229276175138
Sundry debtors333325325263251182138
Cash & bank balances68.8349.3652.1256.3145.9767.8938.88
Loans & advances46740726320816210257.14
Total current assets1,1411,082889756734527372
Total current liabilities420435376297439388219
Net working capital720647513459295139153
Total assets1,4991,336915811628471444
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash27.3816.9521.6715.8041.3913.649.60
Net cash from operating activities32.6432.0673.37(91.17)(60.24)50.8311.02
Net cash from investing activities(126)(322)(83.30)(46.51)(31.68)(70.35)(12.46)
Net cash from financing activities97.403005.2014466.3347.275.49
Net change in cash3.8110.44(4.72)5.86(25.58)27.754.04
Closing cash68.8349.3652.1256.3145.9767.8938.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.3%+7.2%+19.3%-8.4%+30.2%+39.3%-
EBITDA growth-27.8%+9.7%+99.5%-41.8%+15.3%+73.0%-
PBT growth-22.7%+14.6%+142.9%-56.0%+28.6%+151.9%+34.0%
Net income growth-46.0%+22.7%+148.7%-62.0%+4.7%+189.2%-
Revenue CAGR (3Y)+8.4%+5.4%+12.5%+18.4%+26.3%+25.1%+12.7%
EBITDA CAGR (3Y)+16.5%+8.4%+10.2%+5.1%+26.5%+22.3%+3.7%
Profitability & leverage
Net income margin+5.3%+6.5%+5.7%+2.7%+6.6%+8.2%+3.9%
Return on capital employed+7.9%+14.7%+16.1%+8.0%+21.7%+20.9%+8.5%
Return on net worth+5.4%+11.8%+12.1%+5.8%+20.3%+25.9%+10.2%
Debt / equity0.130.070.030.030.040.210.49
Long-term debt / equity0.070.020.000.000.000.000.01
Interest cover18.405.752.963.84-6.762.036.27
Efficiency & per share
Fixed asset turnover2.222.502.652.232.491.721.04
Inventory turnover6.326.607.085.626.867.577.33
Debtors turnover5.495.585.755.527.157.436.29
EPS (₹)1.732.151.880.762.132.160.75
Dividend per share (₹)0.200.200.000.000.000.000.00
Book value per share (₹)22.7521.1016.5814.7311.568.476.32
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue678541463458370391382403
Revenue growth (YoY)+83.5%+38.3%+21.2%+13.5%-3.7%+1.5%--
Other income8.435.318.823.935.754.093.144.87
Total expenses568461440416342372352372
EBITDA11079.6023.3141.8927.9318.9530.1631.57
EBITDA margin+16.2%+14.7%+5.0%+9.2%+7.6%+4.8%+7.9%+7.8%
Depreciation9.707.980.6310.0910.707.8812.254.81
Interest5.104.783.874.314.113.813.741.27
Profit before tax10472.1527.6331.4218.8711.3517.3130.36
Tax25.7818.157.507.934.493.295.407.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6811,5551,5381,3391,4491,112792
Revenue growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
Other income22.5915.7212.575.7610.2411.779.42
Total expenses1,5691,4011,3761,2621,3201,000728
Employee cost20617716014615012398.07
EBITDA11215316277.2712911264.47
EBITDA margin+6.7%+9.9%+10.5%+5.8%+8.9%+10.1%+8.1%
Depreciation29.3124.4421.9018.0121.1928.1134.43
Interest16.107.103.511.98(7.37)1.791.97
Profit before tax89.2613814963.0412694.2437.49
Tax23.2036.0138.0416.8024.480.005.15
Net profit64.6810211146.2410194.2432.34
Net profit margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
EPS (₹)1.211.852.170.902.122.100.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11011010210295.5689.9689.96
Reserves & surplus1,1331,072787678476311217
Shareholders' funds (net worth)1,2431,182889780598445307
Secured loans44.2453.9628.1925.1618.5717.0513.43
Unsecured loans16041.550.000.000.000.00129
Total debt20595.5128.1925.1618.5717.05142
Total liabilities1,6131,314949836645488474
Assets
Gross block665649477512479516642
Net block403366217171156144135
Capital work in progress8.2228.3424.4517.0114.151.960.00
Investments110205126118118119119
Inventories257286220211258170132
Sundry debtors333294317255222156121
Cash & bank balances59.4046.3350.4855.9045.5566.9838.03
Loans & advances26340325520815110156.35
Total current assets9131,029843731677493348
Total current liabilities278400328267385359188
Net working capital635629515464291133160
Total assets1,6131,314949836645488474
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash24.4315.3021.2615.3840.4712.799.36
Net cash from operating activities20.4729.0877.36(102)(68.87)49.3110.86
Net cash from investing activities(119)(280)(83.60)(36.20)(22.64)(69.09)(12.08)
Net cash from financing activities97.122600.2814466.4147.464.65
Net change in cash(1.43)9.12(5.96)5.88(25.09)27.683.43
Closing cash59.4046.3350.4855.9045.5566.9838.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+1.1%+14.8%-7.6%+30.3%+40.5%-
EBITDA growth-27.0%-5.2%+109.4%-40.2%+14.9%+74.3%-
PBT growth-35.1%-7.6%+136.3%-49.8%+33.2%+151.4%+31.0%
Net income growth-36.3%-8.4%+139.9%-54.3%+7.3%+191.4%-
Revenue CAGR (3Y)+7.9%+2.4%+11.4%+19.1%+26.4%+25.7%+13.1%
EBITDA CAGR (3Y)+13.2%+5.9%+12.9%+6.2%+25.7%+23.1%+2.2%
Profitability & leverage
Net income margin+3.9%+6.5%+7.2%+3.5%+7.0%+8.5%+4.1%
Return on capital employed+7.2%+12.8%+17.1%+8.8%+20.9%+19.6%+8.0%
Return on net worth+5.5%+9.8%+13.3%+6.7%+19.4%+24.4%+9.9%
Debt / equity0.120.060.030.030.030.210.48
Long-term debt / equity0.070.020.000.000.000.000.00
Interest cover19.455.502.513.34-6.832.126.56
Efficiency & per share
Fixed asset turnover2.562.763.112.702.911.921.12
Inventory turnover6.196.147.135.706.777.377.09
Debtors turnover5.365.095.375.617.688.036.51
EPS (₹)1.211.852.170.902.122.100.72
Dividend per share (₹)0.200.200.000.000.000.000.00
Book value per share (₹)22.6821.5617.3915.2611.978.926.83

Timeline of Morepen Laboratories

4 dated milestones of Morepen Laboratories across 37 years, from founding to its latest funding, stage changes and deals.

  1. Founded Morepen Laboratories is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $100.0M.
  4. Funding Latest funding round, Post-IPO, of $59.2M.

Web traffic of Morepen Laboratories

The website of Morepen Laboratories (morepen.com) receives about 20.4K visits a month and ranks #1,439,185 among all websites worldwide, #1,869 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    20.4K

    ▲ 10.2% vs previous month

  • Unique visitors
    9.4K

    per month

  • Global rank
    #1,439,185

    among all websites

  • Category rank
    #1,869

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Morepen Laboratories. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Zydus Cadila
zyduscadila.com
100%
25.8K#1,058,292View details
merck.co.in
merck.co.in
91%
–
lupinworld.com
lupinworld.com
83%
–
Mangalam Drugs
mangalamdrugs.com
82%
9.9K#1,747,627View details
Nectar Lifesciences
neclife.com
80%
4.6K#4,844,386View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 18 similar websites and full traffic analytics for Morepen Laboratories

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 18 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Morepen Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Morepen Laboratories

MOREPENLAB: Q2 CONS NET PROFIT 889M RUPEES VS 410M (YOY)
Exchange Update • 15 days ago
MOREPENLAB: Q2 REVENUE 7.5B RUPEES VS 4.1B (YOY)
Exchange Update • 15 days ago
MOREPENLAB: Q2 EBITDA 1.23B RUPEES VS 307M (YOY); Q2 EBITDA MARGIN 16.5% VS 7.5% (YOY)
Exchange Update • 15 days ago
Morepen files first US drug application, eyes generic diabetes market - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Morepen Strengthens Integrated CDMO Capabilities with First U.S. ANDA Submission for Sitagliptin Tablets
Business Standard • 1 month ago
Morepen Labs: Co.submits First U.S. Anda For Sitagliptin, Strengthens Integrated Cdmo Capabilities. First U.s. Anda Submitted For Sitagliptin Tablets Usp In Three Strengths
Exchange Update • 1 month ago
Morepen Laboratories Ltd June-Quarter Consol Net Profit 563.5 Million Rupees
Reuters • 3 months ago
Morepen Clocks Highest-Ever Quarterly Revenue and Earnings in Q1'FY27; EBITDA Grows by 207% and PAT by 394%; CDMO Enters Full Scale Commercialization
Business Standard • 3 months ago
Morepen Laboratories March-Quarter Consol Net Profit 157 Million Rupees
Reuters • 5 months ago
Morepen Laboratories Says USFDA Clears Masulkhana API Facility With Nil Form 483 Observations
Reuters • 6 months ago
Premium access

Complete news archive for Morepen Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Morepen Laboratories

Morepen Laboratories was founded in 1984 and raised its 1st funding round 37 years after it was founded.

Morepen Laboratories is headquartered in Solan, India. It is registered at Solan, Himachal Pradesh, India.

Sanjay Suri is the CEO of Morepen Laboratories, as recorded in our data.

Morepen Laboratories has 1,104 employees.

The primary company behind Morepen Laboratories, Morepen Laboratories Limited, reported revenue of ₹1,853 Cr for FY 2026, down 0% year on year.

Morepen Laboratories was established in 1984 in Solan, India, within the pharmaceuticals sector. Active pharmaceutical ingredients, formulations, diagnostic tools, and fast-moving health goods are produced and distributed. Over-the-counter healthcare items, nutraceuticals, wellness solutions, and healthy cures form part of the portfolio. Self-care devices, including blood pressure and glucose monitors, are also supplied to support consumer health needs.

Morepen Laboratories offers Active Pharmaceutical Ingredients and Home Diagnostics.

Yes, Morepen Laboratories is publicly traded on NSE under the ticker symbol MOREPENLAB.

Morepen Laboratories has 1 investor. Key investors include Corinth Group of Switzerland.

Morepen Laboratories operates through Morepen Laboratories Limited.

The legal entities of Morepen Laboratories currently have 8 directors, including Savita, Sushil Suri, Sanjay Suri and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available